Eurofins to invest millions in new UK facility
Monday, March 20, 2017
20 March 2017
Eurofins to invest millions in new UK facility
Eurofins Scientific (EUFI.PA), a world leader in bioanalytical testing, has announced plans to establish a new pharmaceutical chemistry and microbiology facility in Livingston, Scotland as part of a £4 million investment.
The announcement follows Eurofins’ acquisition of Exova’s pharmaceutical, food and water testing business in the UK & Ireland in July 2016, and the subsequent purchase of ILS’s pharmaceutical business in October 2016.
Significantly increasing its capacity in the UK, the 5800 m2 facility at Brucefield Industry Park will house Eurofins’ Biopharmaceutical Testing business in the UK, currently based in Edinburgh. The first phase of the project will see the development of 1400m2 of lab space and creates the scope for significant expansion.
Alison Clayton, general manager at Eurofins BioPharma Product Testing commented: “It’s an exciting time for Eurofins as we strengthen our footprint in the UK and Ireland. The new facility offers significant capacity for future growth, as well as the space to take on new projects more rapidly and react to customer needs more flexibly.
“The purpose-built lab space will also help to improve productivity, meaning we can provide a more streamlined and efficient service to biopharmaceutical companies accessing our analytical testing services.
“From the new facility, Eurofins BioPharma Product Testing UK will provide a range of GMP pharmaceutical testing services, including, but not exclusively method development and validation, finished product and raw material testing, elemental impurity testing, micro testing and stability studies.”
As part of the investment, Eurofins BioPharma Product Testing UK will be purchasing a new inductively coupled plasma mass spectrometry (ICP-MS) machine, enabling the company to meet growing demand for this service. Eurofins will also invest in more high-performance liquid chromatography (HPLC) equipment, increasing its capacity by 40 per cent.
Alison continued: “At Eurofins BioPharma Product Testing UK, we are committed to adapting and growing our offering in line with customers’ evolving needs. Following the introduction of the International Conference on Harmonization (ICH), Q3D Guideline for Elemental Impurities relating to existing drug products in the US and Europe, we have seen greater demand for more quantitative methods of elemental analysis such as the use of ICP-MS technology.
“From the 1st January 2018, these regulations will apply to both new and existing drug products, so by investing now, we are preparing for future demand and market requirements.”
For further information on Eurofins BioPharma Product Testing UK, please visit: http://www.eurofins.ie/biopharma-services/
Picture caption: Eurofins’ facility at Brucefield Industry Park, Livingston, Scotland
For further information, images and interview opportunities, please contact Lindsay Baldry at ramarketing: firstname.lastname@example.org | 0191 222 1242 | ramarketingpr.com | Twitter: @ramarketingpr | Facebook: /ramarketingpr | LinkedIn: /ramarketing
Notes to editors:
Eurofins - a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 27,000 staff in 310 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantee can be made as to their validity.